Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,116
  • Shares Outstanding, K 3,267
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,120 K
  • EBIT $ -12 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.92
  • Number of Estimates 1
  • High Estimate -0.92
  • Low Estimate -0.92
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -283.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +47.06%
on 11/22/24
1.5000 -16.67%
on 12/10/24
+0.1800 (+16.82%)
since 11/12/24
3-Month
0.8500 +47.06%
on 11/22/24
1.5000 -16.67%
on 12/10/24
-0.0900 (-6.72%)
since 09/12/24
52-Week
0.8500 +47.06%
on 11/22/24
16.0000 -92.19%
on 12/13/23
-14.9700 (-92.29%)
since 12/12/23

Most Recent Stories

More News
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

PCSA : 1.2500 (-0.79%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.8357 (-2.11%)
PCSA : 1.2500 (-0.79%)
JAGX : 0.9751 (-23.82%)
BCTX : 0.6612 (-39.89%)
ONC.TO : 1.20 (-1.64%)
RHHBY : 35.5700 (-1.19%)
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022

HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B marketExpect top line...

PCSA : 1.2500 (-0.79%)
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...

PCSA : 1.2500 (-0.79%)

Business Summary

Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who have unmet medical need. Processa Pharmaceuticals Inc., formerly known as Heatwurx Inc., is based in HANOVER, United States.

See More

Key Turning Points

3rd Resistance Point 1.5157
2nd Resistance Point 1.4229
1st Resistance Point 1.3364
Last Price 1.2500
1st Support Level 1.1571
2nd Support Level 1.0643
3rd Support Level 0.9778

See More

52-Week High 16.0000
Fibonacci 61.8% 10.2127
Fibonacci 50% 8.4250
Fibonacci 38.2% 6.6373
Last Price 1.2500
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar